Yes, great article. Thanks for sharing Cabel. As Growacet pointed out, it gives some attention to Constellation, who also is in the BET inhibitor field. However, Constellation's CPI-0610 compound, along with pretty much every other BET inhibitor in clinical development other than apabetalone, is a pan-BET inhibitor being developed in the oncology space. Apabetalone is a bromodomain-2 selective BET inhibitor, whereas the pan-BET inhibitors are not selective. Constellation is much more a competitor for Zenith than for Resverlogix, since Zenith's ZEN-3694 is also a pan-BET inhibitor. However, good news of any kind for anyone in the BET inhibitor space is good for all BET inhibitor companies right now, including Resverlogix, to get more attention.

BearDownAZ